MCTA vs DBVT

Charming Medical Limited Class A Ordinary Shares (MCTA) offers the better valuation at 414.

5x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Charming Medical Limited Class A Ordinary Shares (MCTA) delivered a total return of +319.

3%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: MCTA returned +319. 3% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

On balance sheet safety, DBV Technologies S.

A. (DBVT) carries a lower debt/equity ratio of 13% versus 24% for Charming Medical Limited Class A Ordinary Shares — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Charming Medical Limited Class A Ordinary Shares grew EPS 54.

2% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Charming Medical Limited Class A Ordinary Shares (MCTA) is the more profitable company, earning 19.

3% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 19. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCTA leads at 22. 3% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — MCTA leads at 67. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, DBV Technologies S.

A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Both have compounded well over 10 years (DBVT: -87. 0%, MCTA: +319. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.